Combination immunotherapy for advanced lung cancer.

S. C. Yang, E. A. Grimm, J. A. Roth

Research output: Contribution to journalArticlepeer-review

Abstract

Therapeutic strategies using cytokines have not been extensively tested in patients with advanced non-small-cell lung cancer (NSCLC). We developed a basic laboratory and clinical research program to investigate the effective immunotherapeutic manipulations for activating the endogenous immune system with biological agents. Our efforts using low-dose interleukin 2 in conjunction with other biologic response modifiers for the treatment of NSCLC are summarized here.

Original languageEnglish (US)
Pages (from-to)197-201
Number of pages5
JournalJournal of the National Cancer Institute. Monographs
Issue number13
StatePublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Combination immunotherapy for advanced lung cancer.'. Together they form a unique fingerprint.

Cite this